1Hoermann G, Cerny-Reiterer S, Sadovnik I,et al. Oncostatin Mis a FIP1L1 /PDGFRA-dependent mediator of cytokine productionin chronic eosinophilic leukemia[J]. Allergy,2013,68(6) :713-723. 被引量：1
2Rumi E,Milosevic JD, Casetti I, et al. Efficacy of ruxolitinib inchronic eosinophilic leukemia associated with a PCM1-JAK2 fu-sion gene[J]. J Clin Oncol,2013,31(17):e269-271 ?. 被引量：1
3Vardiman JW,Thiele J, Arber DA ,et al. The 2008 revision of theWorld Health Organization (WHO) classification of myeloid neo-plasms and acute leukemia : rationale and important changes [J].Blood,2009,114(5) :937-951. 被引量：1
6Klion AD. How I treat hypereosinophilic syndromes [J]. Blood,2009,114(18):3736-3741. 被引量：1
7Valent P. Pathogenesis, classification, and therapy of eosinophiliaand eosinophil disorders [J]. Blood Rev, 2009,23 (4) : 157-165. 被引量：1
8Gleich GJ,Leiferman KM. The hypereosinophilic syndromes :current concepts and treatments [J]. Br J Haematol, 2009,145(3):271-285. 被引量：1
9Salemi S ,Yousefi S ,Simon D ,et al. A novel FIP1LI-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome[J]. Allergy, 2009,64 (6) :913-918. 被引量：1
